Marija Mihailovich

Dr. Marija Mihailovich

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2010 in BioEssays
Verified
Journal Article
Closed access
PDF file
MMMarija Mihailovich
Marija Mihailovich
CMCristina Militti
Cristina Militti
TGToni Gabaldon
Toni Gabaldon
FGFatima Gebauer
Fatima Gebauer

10 November 2015 in Nature Communications
Verified
Journal Article
Open access
PDF file
MMMarija Mihailovich
Marija Mihailovich
MBMichael Bremang
Michael Bremang
VSValeria Spadotto
Valeria Spadotto
DMDaniele Musiani
Daniele Musiani
EVElena Vitale
Elena Vitale
Tiziana BonaldiTiziana Bonaldi
Tiziana Bonaldi
The synergism between c-MYC and miR-17-19b, a truncated version of the miR-17-92 cluster, is well-documented during tumor initiation. However, little is known about miR-17-19b function in established cancers. Here we investigate the role of miR-17-19b in c-MYC-driven lymphomas by integrating SILAC-based quantitative proteomics, transcriptomics and 3′ untranslated region (UTR) analysis upon miR-17-19b overexpression. We identify over one hundred miR-17-19b targets, of which 40% are co-regulated by c-MYC. Downregulation of a new miR-17/20 target, checkpoint kinase 2 (Chek2), increases the recruitment of HuR to c-MYC transcripts, resulting in the inhibition of c-MYC translation and thus interfering with in vivo tumor growth. Hence, in established lymphomas, miR-17-19b fine-tunes c-MYC activity through a tight control of its function and expression, ultimately ensuring cancer cell homeostasis. Our data highlight the plasticity of miRNA function, reflecting changes in the mRNA landscape and 3′ UTR shortening at different stages of tumorigenesis.

6 December 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
MZMatteo Zanella
Matteo Zanella
AVAlessandro Vitriolo
Alessandro Vitriolo
AAAlejandro Andirko
Alejandro Andirko
PMPedro Tiago Martins
Pedro Tiago Martins
SSStefanie Sturm
Stefanie Sturm
GTGiuseppe Testa
Giuseppe Testa
Dissecting the BAZ1B genetic circuitry in the neural crest brings out its critical role in shaping the modern human face.

8 March 2004 in Nucleic Acids Research
Verified
Journal Article
Closed access
DTDavide De Pietri Tonelli
Davide De Pietri Tonelli
MMMarija Mihailovich
Marija Mihailovich
ACAlessandra Di Cesare
Alessandra Di Cesare
FCFranca Codazzi
Franca Codazzi
FGFabio Grohovaz
Fabio Grohovaz
DZDaniele Zacchetti
Daniele Zacchetti
As the main beta-secretase of the central nervous system, BACE-1 is a key protein in the pathogenesis of Alzheimer's disease. Excessive expression of the protein might cause an overproduction of the neurotoxic beta-amyloid peptide. Therefore, a tight regulation of BACE-1 expression is expected in vivo. In addition to a possible transcriptional control, the BACE-1 transcript leader contains features that might constitute mechanisms of translational regulation of protein expression. Moreover, recent work has revealed an increase of BACE-1 protein and beta-secretase activity in some Alzheimer's disease patients, although a corresponding increase of transcript has not been reported. Here we show that BACE-1 translation could be modulated at multiple stages. The presence of several upstream ATGs strongly reduces the translation of the main open reading frame. This inhibition could be overcome with conditions that favour skipping of upstream ATGs. We also report an alternative splicing of the BACE-1 transcript leader that reduces the number of upstream ATGs. Finally, we show that translation driven by the BACE-1 transcript leader is increased in activated astrocytes independently of the splicing event, indicating yet another mechanism of translational control. Our findings might explain why increases in BACE-1 protein or activity are reported in the brain of Alzheimer's disease patients even in the absence of changes in transcript levels.

16 April 2007 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MMMarija Mihailovich
Marija Mihailovich
RTRolf Thermann
Rolf Thermann
FGFabio Grohovaz
Fabio Grohovaz
MHMatthias W. Hentze
Matthias W. Hentze
DZDaniele Zacchetti
Daniele Zacchetti
BACE1 is the protease responsible for the production of amyloid-β peptides that accumulate in the brain of Alzheimer's disease (AD) patients. BACE1 expression is regulated at the transcriptional, as well as post-transcriptional level. Very high BACE1 mRNA levels have been observed in pancreas, but the protein and activity were found mainly in brain. An up-regulation of the protein has been described in some AD patients without a change in transcript levels. The features of BACE1 5′ untranslated region (5 ′ UTR), such as the length, GC content, evolutionary conservation and presence of upstream AUGs (uAUGs), indicate an important regulatory role of this 5′ UTR in translational control. We demonstrate that, in brain and pancreas, almost all of the native BACE1 mRNA contains the full-length 5′ UTR. RNA transfection and in vitro translation show that translation is mainly inhibited by the presence of the uAUGs. We provide a mutational analysis that highlight the second uAUG as the main inhibitory element while mutations of all four uAUGs fully de-repress translation. Furthermore, we have evidence that a sequence within the region 222-323 of the BACE1 5′ UTR has a stimulatory effect on translation that might depend on the presence of trans -acting factors.

1 December 2023 in Science Advances
Verified
Journal Article
Open access
ALAlejandro López-Tobón
Alejandro López-Tobón
RSReinald Shyti
Reinald Shyti
CVCarlo Emanuele Villa
Carlo Emanuele Villa
CCCristina Cheroni
Cristina Cheroni
PFPatricio Fuentes-Bravo
Patricio Fuentes-Bravo
GTGiuseppe Testa
Giuseppe Testa
Copy number variations at 7q11.23 cause neurodevelopmental disorders with shared and opposite manifestations. Deletion causes Williams-Beuren syndrome featuring hypersociability, while duplication causes 7q11.23 microduplication syndrome (7Dup), frequently exhibiting autism spectrum disorder (ASD). Converging evidence indicates GTF2I as key mediator of the cognitive-behavioral phenotypes, yet its role in cortical development and behavioral hallmarks remains largely unknown. We integrated proteomic and transcriptomic profiling of patient-derived cortical organoids, including longitudinally at single-cell resolution, to dissect 7q11.23 dosage–dependent and GTF2I -specific disease mechanisms. We observed dosage-dependent impaired dynamics of neural progenitor proliferation, transcriptional imbalances, and highly specific alterations in neuronal output, leading to precocious excitatory neuron production in 7Dup, which was rescued by restoring physiological GTF2I levels. Transgenic mice with Gtf2i duplication recapitulated progenitor proliferation and neuronal differentiation defects alongside ASD-like behaviors. Consistently, inhibition of lysine demethylase 1 (LSD1), a GTF2I effector, was sufficient to rescue ASD-like phenotypes in transgenic mice, establishing GTF2I -LSD1 axis as a molecular pathway amenable to therapeutic intervention in ASD.